Abacus Planning Group’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $616K | Buy |
25,600
+120
| +0.5% | +$3.14K | 0.08% | 126 |
|
|
2026
Q1 | $715K | Sell |
25,480
-1,734
| -6% | -$46.2K | 0.1% | 110 |
|
|
2025
Q4 | $678K | Buy |
27,214
+4,832
| +22% | +$122K | 0.09% | 106 |
|
|
2025
Q3 | $570K | Sell |
22,382
-415
| -2% | -$10.2K | 0.08% | 114 |
|
|
2025
Q2 | $553K | Buy |
22,797
+118
| +0.5% | +$2.75K | 0.08% | 117 |
|
|
2025
Q1 | $575K | Buy |
22,679
+34
| +0.2% | +$890 | 0.1% | 103 |
|
|
2024
Q4 | $601K | Sell |
22,645
-303
| -1% | -$8.22K | 0.11% | 101 |
|
|
2024
Q3 | $664K | Buy |
22,948
+1,046
| +5% | +$30.5K | 0.12% | 93 |
|
|
2024
Q2 | $613K | Sell |
21,902
-4,657
| -18% | -$128K | 0.12% | 97 |
|
|
2024
Q1 | $737K | Buy |
26,559
+980
| +4% | +$27.2K | 0.14% | 85 |
|
|
2023
Q4 | $736K | Sell |
25,579
-482
| -2% | -$14.6K | 0.16% | 86 |
|
|
2023
Q3 | $864K | Sell |
26,061
-1,658
| -6% | -$58.6K | 0.21% | 75 |
|
|
2023
Q2 | $1.02M | Buy |
27,719
+1,159
| +4% | +$45.1K | 0.25% | 61 |
|
|
2023
Q1 | $1.08M | Buy |
26,560
+19
| +0.1% | +$821 | 0.28% | 54 |
|
|
2022
Q4 | $1.36M | Sell |
26,541
-195
| -0.7% | -$9.35K | 0.37% | 46 |
|
|
2022
Q3 | $1.17M | Buy |
26,736
+598
| +2% | +$29.1K | 0.35% | 50 |
|
|
2022
Q2 | $1.37M | Buy |
26,138
+230
| +0.9% | +$11.7K | 0.4% | 44 |
|
|
2022
Q1 | $1.34M | Sell |
25,908
-30
| -0.1% | -$1.56K | 0.36% | 49 |
|
|
2021
Q4 | $1.53M | Buy |
25,938
+1,678
| +7% | +$83.1K | 0.41% | 51 |
|
|
2021
Q3 | $1.04M | Buy |
24,260
+175
| +0.7% | +$7.75K | 0.33% | 53 |
|
|
2021
Q2 | $943K | Sell |
24,085
-4,232
| -15% | -$165K | 0.29% | 62 |
|
|
2021
Q1 | $1.03M | Buy |
28,317
+966
| +4% | +$34.3K | 0.33% | 61 |
|
|
2020
Q4 | $1.01M | Sell |
27,351
-1,152
| -4% | -$42.3K | 0.31% | 61 |
|
|
2020
Q3 | $992K | Buy |
28,503
+307
| +1% | +$10.8K | 0.36% | 57 |
|
|
2020
Q2 | $875K | Sell |
28,196
-318
| -1% | -$10.8K | 0.36% | 59 |
|
|
2020
Q1 | $883K | Sell |
28,514
-137
| -0.5% | -$4.67K | 0.43% | 46 |
|
|
2019
Q4 | $1.06M | Sell |
28,651
-155
| -0.5% | -$5.52K | 0.49% | 40 |
|
|
2019
Q3 | $982K | Buy |
28,806
+5,180
| +22% | +$188K | 0.49% | 45 |
|
|
2019
Q2 | $971K | Sell |
23,626
-1,600
| -6% | -$63.5K | 0.58% | 37 |
|
|
2019
Q1 | $1.02M | Buy |
25,226
+1,073
| +4% | +$43K | 0.64% | 35 |
|
|
2018
Q4 | $1M | Buy |
24,153
+1,133
| +5% | +$47K | 0.76% | 30 |
|
|
2018
Q3 | $962K | Sell |
23,020
-2,433
| -10% | -$93.7K | 0.65% | 34 |
|
|
2018
Q2 | $876K | Buy |
25,453
+657
| +3% | +$22.5K | 0.66% | 35 |
|
|
2018
Q1 | $835K | Buy |
24,796
+5,654
| +30% | +$194K | 0.68% | 34 |
|
|
2017
Q4 | $658K | Buy |
+19,142
| New | +$653K | 0.67% | 38 |
|
Other funds holding PFE
Abacus Planning Group's PFE Position: Q2 2026 in Review
Abacus Planning Group increased its Pfizer (PFE) stake by 0.47% in Q2 2026, buying an estimated $3.14K and bringing the position to 25,600 shares worth $616K. The position accounts for 0.08% of the portfolio, ranked #126.
Abacus Planning Group first reported a position in PFE in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.53M in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Abacus Planning Group held 25,600 shares of Pfizer worth $616K as of Q2 2026.
- Abacus Planning Group bought 120 Pfizer shares in Q2 2026, an estimated $3.14K.
- Pfizer made up 0.08% of Abacus Planning Group's portfolio in Q2 2026, its #126 holding.
- Abacus Planning Group first reported a position in Pfizer in Q4 2017 and has held it in 35 quarters since.
- Abacus Planning Group's Pfizer position peaked at $1.53M in Q4 2021.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Abacus Planning Group's 13F filing for Q2 2026, filed 20 Jul 2026.